viltepso Drug Patent Profile
✉ Email this page to a colleague
When do Viltepso patents expire, and what generic alternatives are available?
Viltepso is a drug marketed by Nippon Shinyaku and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-three patent family members in twenty countries.
The generic ingredient in VILTEPSO is viltolarsen. One supplier is listed for this compound. Additional details are available on the viltolarsen profile page.
DrugPatentWatch® Generic Entry Outlook for Viltepso
Viltepso was eligible for patent challenges on August 12, 2024.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be August 31, 2031. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for viltepso?
- What are the global sales for viltepso?
- What is Average Wholesale Price for viltepso?
Summary for viltepso
International Patents: | 53 |
US Patents: | 2 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 1 |
Drug Prices: | Drug price information for viltepso |
What excipients (inactive ingredients) are in viltepso? | viltepso excipients list |
DailyMed Link: | viltepso at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for viltepso
Generic Entry Date for viltepso*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for viltepso
viltepso is protected by two US patents and two FDA Regulatory Exclusivities.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of viltepso is ⤷ Subscribe.
This potential generic entry date is based on patent ⤷ Subscribe.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
Nippon Shinyaku | VILTEPSO | viltolarsen | SOLUTION;INTRAVENOUS | 212154-001 | Aug 12, 2020 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for viltepso
When does loss-of-exclusivity occur for viltepso?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 11296882
Patent: Antisense nucleic acid
Estimated Expiration: ⤷ Subscribe
Canada
Patent: 09637
Patent: ACIDE NUCLEIQUE ANTISENS (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
China
Patent: 3154245
Patent: Antisense nucleic acid
Estimated Expiration: ⤷ Subscribe
Croatia
Patent: 0160336
Estimated Expiration: ⤷ Subscribe
Patent: 0191770
Estimated Expiration: ⤷ Subscribe
Cyprus
Patent: 17367
Estimated Expiration: ⤷ Subscribe
Denmark
Patent: 12917
Estimated Expiration: ⤷ Subscribe
Patent: 18211
Estimated Expiration: ⤷ Subscribe
European Patent Office
Patent: 12917
Patent: ACIDE NUCLÉIQUE ANTISENS (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 18211
Patent: ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Subscribe
Patent: 43341
Patent: ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Subscribe
Patent: 81655
Patent: ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Subscribe
Hungary
Patent: 27321
Estimated Expiration: ⤷ Subscribe
Patent: 46364
Estimated Expiration: ⤷ Subscribe
Japan
Patent: 2012029986
Patent: アンチセンス核酸
Estimated Expiration: ⤷ Subscribe
Patent: 63655
Estimated Expiration: ⤷ Subscribe
Patent: 41728
Estimated Expiration: ⤷ Subscribe
Patent: 93343
Estimated Expiration: ⤷ Subscribe
Patent: 65932
Estimated Expiration: ⤷ Subscribe
Patent: 47430
Estimated Expiration: ⤷ Subscribe
Patent: 67619
Estimated Expiration: ⤷ Subscribe
Patent: 67620
Estimated Expiration: ⤷ Subscribe
Patent: 67621
Estimated Expiration: ⤷ Subscribe
Patent: 67636
Estimated Expiration: ⤷ Subscribe
Patent: 14054250
Patent: ANTISENSE NUCLEIC ACIDS
Estimated Expiration: ⤷ Subscribe
Patent: 16104021
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 18027083
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 19062913
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 20072724
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 21072820
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 21072821
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 21072822
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 21104037
Patent: アンチセンス核酸 (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 23036865
Patent: アンチセンス核酸
Estimated Expiration: ⤷ Subscribe
Lithuania
Patent: 18211
Estimated Expiration: ⤷ Subscribe
Poland
Patent: 12917
Estimated Expiration: ⤷ Subscribe
Patent: 18211
Estimated Expiration: ⤷ Subscribe
Portugal
Patent: 18211
Estimated Expiration: ⤷ Subscribe
Russian Federation
Patent: 67664
Patent: АНТИСМЫСЛОВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Subscribe
Patent: 13114396
Patent: АНТИСМЫСЛОВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ
Estimated Expiration: ⤷ Subscribe
San Marino
Patent: 01600111
Patent: ACIDI NUCLEICI ANTISENSO
Estimated Expiration: ⤷ Subscribe
Serbia
Patent: 649
Patent: ANTISENS NUKLEINSKE KISELINE (ANTISENSE NUCLEIC ACID)
Estimated Expiration: ⤷ Subscribe
Patent: 361
Patent: ANTISENS NUKLEINSKE KISELINE (ANTISENSE NUCLEIC ACIDS)
Estimated Expiration: ⤷ Subscribe
Slovenia
Patent: 12917
Estimated Expiration: ⤷ Subscribe
Patent: 18211
Estimated Expiration: ⤷ Subscribe
South Korea
Patent: 1310569
Estimated Expiration: ⤷ Subscribe
Patent: 130069762
Patent: ANTISENSE NUCLEIC ACID
Estimated Expiration: ⤷ Subscribe
Spain
Patent: 67411
Estimated Expiration: ⤷ Subscribe
Patent: 50748
Estimated Expiration: ⤷ Subscribe
Taiwan
Patent: 41024
Estimated Expiration: ⤷ Subscribe
Patent: 1215408
Patent: Antisense nucleic acid
Estimated Expiration: ⤷ Subscribe
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering viltepso around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Spain | 2750748 | ⤷ Subscribe | |
Japan | 2023036865 | アンチセンス核酸 | ⤷ Subscribe |
European Patent Office | 3018211 | ACIDES NUCLÉIQUES ANTISENS (ANTISENSE NUCLEIC ACIDS) | ⤷ Subscribe |
Japan | 2021104037 | アンチセンス核酸 (ANTISENSE NUCLEIC ACID) | ⤷ Subscribe |
Japan | 2021072821 | アンチセンス核酸 (ANTISENSE NUCLEIC ACID) | ⤷ Subscribe |
Taiwan | I541024 | ⤷ Subscribe | |
Russian Federation | 2567664 | АНТИСМЫСЛОВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ (ANTISENSE NUCLEIC ACIDS) | ⤷ Subscribe |
>Country | >Patent Number | >Title | >Estimated Expiration |
Viltepso Market Analysis and Financial Projection Experimental
More… ↓